Associations - Adcetris (brentuximab vedotin)

No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
TNFRSF8 positive	Hodgkin Lymphoma	TNFRSF8 positive	Hodgkin Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
TNFRSF8 positive	Cutaneous T-cell Lymphoma	TNFRSF8 positive	Cutaneous T-cell Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
TNFRSF8 expression	Peripheral T-cell Lymphoma	TNFRSF8 expression	Peripheral T-cell Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	nivolumab + brentuximab vedotin Sensitive: A2 - Guideline nivolumab + brentuximab vedotin Sensitive : A2	nivolumab + brentuximab vedotin Sensitive: A2 - Guideline nivolumab + brentuximab vedotin Sensitive : A2
TNFRSF8 positive	Diffuse Large B Cell Lymphoma	TNFRSF8 positive	Diffuse Large B Cell Lymphoma	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2
TNFRSF8 positive	Peripheral T-cell Lymphoma	TNFRSF8 positive	Peripheral T-cell Lymphoma	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2
ALK positive	T Cell Non-Hodgkin Lymphoma	ALK positive	T Cell Non-Hodgkin Lymphoma	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B
ALK positive	Non-Hodgkin’s Lymphoma	ALK positive	Non-Hodgkin’s Lymphoma	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B
TNFRSF8 expression	Cutaneous T-cell Lymphoma	TNFRSF8 expression	Cutaneous T-cell Lymphoma	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B
TNFRSF8 expression	T Cell Non-Hodgkin Lymphoma	TNFRSF8 expression	T Cell Non-Hodgkin Lymphoma	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B
TNFRSF8 expression	Acute Myelogenous Leukemia	TNFRSF8 expression	Acute Myelogenous Leukemia	brentuximab vedotin Sensitive: C1 - Off-label brentuximab vedotin Sensitive : C1	brentuximab vedotin Sensitive: C1 - Off-label brentuximab vedotin Sensitive : C1
ABCC2 underexpression	Hodgkin Lymphoma	ABCC2 underexpression	Hodgkin Lymphoma	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials nivolumab + brentuximab vedotin Sensitive : C3	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials nivolumab + brentuximab vedotin Sensitive : C3
PD-1 underexpression	Hodgkin Lymphoma	PD-1 underexpression	Hodgkin Lymphoma	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials nivolumab + brentuximab vedotin Sensitive : C3	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials nivolumab + brentuximab vedotin Sensitive : C3
CD163 overexpression	Hodgkin Lymphoma	CD163 overexpression	Hodgkin Lymphoma	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials nivolumab + brentuximab vedotin Sensitive : C3	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials nivolumab + brentuximab vedotin Sensitive : C3
CD14 overexpression	Hodgkin Lymphoma	CD14 overexpression	Hodgkin Lymphoma	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials nivolumab + brentuximab vedotin Sensitive : C3	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials nivolumab + brentuximab vedotin Sensitive : C3
TNFRSF8 overexpression	Hodgkin Lymphoma	TNFRSF8 overexpression	Hodgkin Lymphoma	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials nivolumab + brentuximab vedotin Sensitive : C3	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials nivolumab + brentuximab vedotin Sensitive : C3
TNFRSF8 expression	Diffuse Large B Cell Lymphoma	TNFRSF8 expression	Diffuse Large B Cell Lymphoma	rituximab + brentuximab vedotin Sensitive: C3 – Early Trials rituximab + brentuximab vedotin Sensitive : C3	rituximab + brentuximab vedotin Sensitive: C3 – Early Trials rituximab + brentuximab vedotin Sensitive : C3
TNFRSF8 positive	Lymphoma	TNFRSF8 positive	Lymphoma	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials nivolumab + brentuximab vedotin Sensitive : C3	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials nivolumab + brentuximab vedotin Sensitive : C3
TNFRSF8 negative	Peripheral T-cell Lymphoma	TNFRSF8 negative	Peripheral T-cell Lymphoma	rituximab + lenalidomide + brentuximab vedotin Sensitive: C4 – Case Studies rituximab + lenalidomide + brentuximab vedotin Sensitive : C4	rituximab + lenalidomide + brentuximab vedotin Sensitive: C4 – Case Studies rituximab + lenalidomide + brentuximab vedotin Sensitive : C4
MYC amplification + BCL2 amplification + TNFRSF8 expression	Diffuse Large B Cell Lymphoma	MYC amplification + BCL2 amplification + TNFRSF8 expression	Diffuse Large B Cell Lymphoma	brentuximab vedotin Sensitive: C4 – Case Studies brentuximab vedotin Sensitive : C4	brentuximab vedotin Sensitive: C4 – Case Studies brentuximab vedotin Sensitive : C4
TNFRSF8 overexpression	Lymphoma	TNFRSF8 overexpression	Lymphoma	brentuximab vedotin Sensitive: C4 – Case Studies brentuximab vedotin Sensitive : C4	brentuximab vedotin Sensitive: C4 – Case Studies brentuximab vedotin Sensitive : C4
RANBP2-ALK rearrangement + TNFRSF8 expression	Fibrosarcoma	RANBP2-ALK rearrangement + TNFRSF8 expression	Fibrosarcoma	ceritinib + brentuximab vedotin Sensitive: D – Preclinical ceritinib + brentuximab vedotin Sensitive : D	ceritinib + brentuximab vedotin Sensitive: D – Preclinical ceritinib + brentuximab vedotin Sensitive : D
RANBP2-ALK rearrangement + TNFRSF8 expression	Fibrosarcoma	RANBP2-ALK rearrangement + TNFRSF8 expression	Fibrosarcoma	crizotinib + brentuximab vedotin Sensitive: D – Preclinical crizotinib + brentuximab vedotin Sensitive : D	crizotinib + brentuximab vedotin Sensitive: D – Preclinical crizotinib + brentuximab vedotin Sensitive : D
RANBP2-ALK rearrangement + TNFRSF8 expression	Sarcoma	RANBP2-ALK rearrangement + TNFRSF8 expression	Sarcoma	brentuximab vedotin Resistant: D – Preclinical brentuximab vedotin Resistant : D	brentuximab vedotin Resistant: D – Preclinical brentuximab vedotin Resistant : D
TNFRSF8 positive	Lymphoma	TNFRSF8 positive	Lymphoma	brentuximab vedotin + SGN-CD30C Sensitive: D – Preclinical brentuximab vedotin + SGN-CD30C Sensitive : D	brentuximab vedotin + SGN-CD30C Sensitive: D – Preclinical brentuximab vedotin + SGN-CD30C Sensitive : D

Adcetris (brentuximab vedotin)

Associations
(29)

Associations
(29)

Adcetris (brentuximab vedotin)

Associations(29)

Associations(29)

Associations
(29)

Associations
(29)